Published in final edited form as:

Chemistry. 2013 May 10; 19(20): . doi:10.1002/chem.201300198.

***Illicium* Sesquiterpenes: Divergent Synthetic Strategy and Neurotrophic Activity Studies**

Dr. Lynn Trzoss^a, Dr. Jing Xu^a, Michelle H. Lacoske^a, Prof. Dr. William C. Mobley^b, and Prof. Dr. Emmanuel A. Theodorakis^a

Jing Xu: jix001@ucsd.edu; Emmanuel A. Theodorakis: etheodor@ucsd.edu

^aDepartment of Chemistry and Biochemistry, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0358, USA, Fax: (+)1-858-822-0386

^bDepartment of Neurosciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0752, USA

Abstract

Majucin-type sesquiterpenes from *Illicium* sp., such as jiadifenolide (**2**), jiadifenin (**3**) and (1*R*, 10*S*)-2-oxo-3,4-dehydroxynemajucin (**4**, ODNM), possess a complex caged chemical architecture and remarkable neurotrophic activities. As such, they represent attractive small molecule leads against various neurodegenerative diseases. We present an efficient, enantioselective and unified synthesis of **2**, **3** and **4** and designed analogues that diverge from tetracyclic key intermediate **7**. The synthesis of **7** is highlighted by the use of an enantioselective Robinson annulation reaction (construction of AB rings), a Pd-mediated carbomethoxylation reaction (construction of C ring) and a one-pot oxidative reaction cascade (construction of D ring). Evaluation of the neurotrophic activity of these compounds led to the identification of several highly potent small molecules that significantly enhanced the activity of nerve growth factor (NGF) in PC-12 cells. Moreover, efforts to define the common pharmacophoric motif suggest that substitution at the C-10 center significantly affects bioactivity, while the hemiketal moiety of **2** and **3** and the C-1 substitution might not be critical to the neurotrophic activity.

Keywords

Total synthesis; Sesquiterpene; Natural product; Oxidation; Cascade reactions; Nerve growth factor

Introduction

The discovery of nerve growth factor (NGF)^[1] has fueled intensive research in the area of neurotrophins, a family of polypeptides that play an essential role in the development and maintenance of neurons in both the central and peripheral nervous system.^[2] The binding of NGF to its cell surface receptor leads to a cascade of signaling pathways that promote axonal and dendritic branching. In turn, this activity allows the construction of a neural network that is critical during embryonic development and/or after neuronal injury. Importantly, alterations in neurotrophin levels have been implicated in various neurodegenerative^[2,3] and psychiatric disorders.^[4] Moreover, preclinical studies have suggested that administration of neurotrophins may lead to an effective treatment for various

Correspondence to: Jing Xu, jix001@ucsd.edu; Emmanuel A. Theodorakis, etheodor@ucsd.edu.

Supporting information for this article is available on the WWW under <http://www.chemurj.org/> or from the author.

neurodegenerative disorders.^[5] However, despite such a potential, clinical trials with NGF and related polypeptides have been disappointing since these compounds cannot be delivered orally, they are rapidly degraded in the body and they are inefficient in crossing the blood-brain barrier.^[6] These problems, inherent with most protein-based therapies, have prompted the scientific community to explore non-peptidyl small molecule-based therapeutics.^[7] In principle, these compounds could induce neurite outgrowth by enhancing the activity or inducing the biosynthesis of NGF and related neurotrophic factors.

Natural products, used in traditional medicine^[8,9] or as nutraceuticals,^[10] hold significant promise as tools for biological studies and as privileged structures for the development of new therapeutic agents against neurodegeneration. The *Illicium* species of plants exemplify such a dual potential. Spreading over the eastern North America, Mexico, the West Indies and the eastern Asia, these plants are known for their distinctive star-shaped fruits and characteristic flavors.^[11] Isolation of their chemical constituents has led to the identification of three distinct families of sesquiterpenes: the *seco*-prezizaanes, the anisactones and the *allo*-cedranes.^[11] Among them, the majucin-subfamily of *seco*-prezizaanes is particularly interesting since it contains compounds with potent neurotrophic activities. Members of this family include majucin (**1**),^[12] jiadifenolide (**2**),^[13] jiadifenin (**3**)^[14] and (1*R*,10*S*)-2-oxo-3,4-dehydroxynemajucin (**4**, ODNM)^[15] (Figure 1). Central to their caged architecture is a highly substituted cyclohexane ring (B ring) that is surrounded by three additional rings including a cyclopentane (A ring) and a γ -lactone (C ring). Further functionalization at C-4 and C-10 forms a unique γ -lactone ring (E ring) as in the structure of **2**.^[11] Initial biological studies have shown that compounds **2-4** significantly enhance neurite outgrowth in primary cultured rat cortical neurons or NGF-mediated PC-12 cells at concentrations between 10 to 100 nM. This is particularly interesting since it suggests that these compounds rather than acting independently of NGF, they enhance its activity. Among them, jiadifenolide is reportedly the most active compound inducing neurite outgrowth at 10 nM.^[13]

Due to the combination of a complex ring motif and significant therapeutic potential, these compounds represent attractive targets for synthetic and biological studies.^[16] Despite various successful syntheses of similar sesquiterpenes such as anisatin^[17] and merrillactone,^[18] the synthetic efforts toward the majucin-subtype *seco*-prezizaane-type sesquiterpenes are rather limited.^[19] To date, two impressive syntheses of jiadifenin (**3**) have been reported by the Danishefsky^[20] and Zhai groups.^[21] Intrigued by the synthetic challenge and medicinal potential of these compounds, we sought to develop a unified synthetic strategy. We hypothesized that such a divergent strategy would provide access to a library of related molecules for subsequent structure-activity relationship studies. Herein, we describe this strategy that led to the first enantioselective synthesis^[22] of **2**, **3** and **4** and related analogues. Biological evaluation of these compounds led to the identification of more potent neurotrophic agents and allowed to propose a critical pharmacophoric motif.

Results and Discussion

Divergent retrosynthetic analysis

The key strategic bond disconnections toward a divergent synthesis of **2-4** and related analogues are shown in Scheme 1. We envisioned that these natural products could derive from “core” structure **7** following late stage modifications. Key to the conversion of **7** to (–)-jiadifenolide would be an oxidative translactonization reaction cascade that formed the E ring of **6** leading, after C-10 oxidation and hemiketalization, to **2**. On the other hand, hydroxylation at C-10 of **7** followed by further A-ring functionalization would produce ODNM (**4**). An oxidation and hemiketalization reaction would then form jiadifenin (**3**) from **4**. Furthermore, the divergent functionalization of **7** would produce a set of designed analogues.

We theorized that the tetracyclic motif of **7** could be formed from compound **8** via a sequence of reactions among which the key step is a one-pot oxidation/“6-*exo-tet*” epoxide opening cascade. In turn, the C ring lactone of **8** could arise from a Pd-catalyzed carbomethoxylation. This disconnection opens the possibility to construct compound **8** from a Hajos-Parrish-type enone **9**. Importantly, this compound could be produced from 1,3-cyclopentadione (**10**) via C-9 alkylation followed by an enantioselective Robinson annulation.

Scalable synthesis of core intermediate **7**

Our synthesis of **7** commenced from commercially available dione **10**, that was readily converted to **11** in 2 steps and 63% combined yield.^[23] Robinson annulation of **11** to **9** was accomplished by optimizing the Tu/Zhang conditions.^[23c] At the onset of the study, we found that treatment of **11** with 30% D-prolinamide/PPTS at 80 °C over 12 h afforded **9** in 74% yield and 70% *ee*. On the other hand, at room temperature this reaction needed up to 60 days to completely consume the starting material thus yielding enantiomerically pure (–)-**9** (> 99% *ee*). To balance reaction efficiency with acceptable enantioselectivity we choose to perform this annulation at 40 °C over 14 days producing **9** in 70% yield and 90% *ee* (50 grams scale). Chemo-selective hydride reduction of the C-1 ketone followed by TBS protection^[24] yielded enone **12** (92% combined yield). Stiles' reagent (MMC, MeO₂CMgOMe)^[25] selectively introduced a sensitive carboxylic acid group at C-5, that was subsequently esterified using Meerwein's salt (Et₃O⁺BF₄[–]) to form β-keto ester **13**.^[26] This procedure provides a safer alternative to the commonly used diazomethane-based esterification of a “Hajos-Parrish-type” β-keto acid.^[27] Construction of the C-5 quaternary center was accomplished by forming the extended enolate **14** (TMSOTf/lutidine)^[28] and methylating the “pre-activated” C-5 center of **14** using TBAF/MeI conditions, thereby producing compound **15** as a single diastereomer (43% combined yield from **12**). Construction of the C-ring would require incorporation of a carboxyl group at C-6 and lactonization with the pendant C-14 hydroxyl group. With this in mind, **15** was converted to the silyl-ether **16** via a sequence of three steps that included: (a) global reduction with LiAlH₄; (b) selective TBS- protection of the primary C-14 hydroxyl group; and (c) IBX oxidation of the secondary C-6 hydroxyl group (85% over 3 steps). Treatment of **16** with McMurry reagent (PhNTf₂)^[29] yielded enol triflate **17**, which underwent a Pd(0)-mediated carbomethoxylation^[30] under carbon monoxide atmosphere (1 bar) to produce uncyclized compound **19** (60%) together with a small amount of lactone **8** (23%). Without purification, this mixture was treated with TFA to cleanly produce the desired lactone **8** (69% overall yield from **16**). Similarly, compound **8** can be made from vinyl iodide **18**, albeit in a slightly lowered overall yield (60% from **16**) (Scheme 2).

Possessing a readily functionalizable ABC ring system with two quaternary centers, lactone **8** provided a solid scaffold for further chemical modifications (Scheme 2). Next task was the installation of the C-6–C-7 *trans*-diol moiety as well as the construction of the D-ring lactone. To this end, the electronically deficient C-6–C-7 double bond was stereoselectively epoxidized under alkaline hydrogen peroxide conditions to generate epoxide **20** in 99% yield. This epoxidation proceeded selectively from the α-face in a substrate-controlled manner. Oxidative cleavage of the terminal double bond of **20** proceeded best via an osmium-catalyzed dihydroxylation and *in situ* cleavage of the resulting diol with NaIO₄. The corresponding aldehyde **21** was treated under Jones conditions to form the corresponding carboxylic acid. Concomitant activation of the neighboring epoxide led, in a one-pot reaction cascade, to lactone **22** (70% yield). The absolute stereochemistry of **22** was unambiguously confirmed via a single crystal X-ray analysis.^[31] In addition to **22** we also isolated a small amount (20%) of a desilylated compound, as suggested by ¹H NMR analysis. This byproduct was shown to be lactone **23**, the structure of which was confirmed

by X-ray analysis.^[31] This compound might arise from concomitant cleavage of the C-1 silyl ether under acidic Jones conditions and lactonization of the resulting hydroxyl group with the C-11 carboxylic acid. Another possibility is the rapid desilylation of the C-1 hydroxy moiety resulted in the attack on the C-11 formyl group to form the corresponding lactol followed by the oxidation to give this side product. Attempts to convert **23** to **22** were unsuccessful. Deprotection of the TBS group of **22** using TBAF then afforded the crucial dilactone **7**, the “core intermediate” for the divergent synthesis. Notably, only one column purification was needed for the conversion of triflate **17** to **7** (6 steps). More importantly, the synthesis of **7** from commercially available 1,3-cyclopentadione was readily reproducible and scalable (> 5 grams prepared), thus providing a robust platform for further investigations.

Total synthesis of (–)-jiadifenolide (**2**)

With sufficient amounts of **7** in hand, we sought to establish a strategy for the oxygenation at C-4. At the onset of these studies, we treated **22** with catalytic OsO₄ but could not detect any dihydroxylation product, presumably due to the steric hindrance of the trisubstituted double bond. Interestingly, treatment of **22** with stoichiometric amounts of OsO₄ in the presence of pyridine produced a moderately stable osmium-pyridine complex **24**^[32] that upon treatment under reductive conditions (sodium thiosulfate) yielded a C-3–C-4 *cis*-diol. To our surprise, we observed a rapid and irreversible translactonization between the C-4 and C-11 functionalities that formed **25** containing the E-ring structure of the target molecule (78% from **22**). The resulting C-3 and C-7 secondary hydroxyl groups of **25** were found to be difficult to differentiate. Nonetheless, the tendency of the C-4 hydroxyl group to translactonize suggested a suitable way to construct the E ring of jiadifenolide. With this in mind, compound **7** was treated with *m*CPBA to produce epoxide **26** as a single diastereomer in 80% yield.^[31] We postulated that the selectivity arises from a combination of steric hindrance of the C-5 methyl group and the directing effect of the C-1 hydroxyl group.^[33] Treatment of **7** with Dess-Martin-periodinane initiated the desired oxidative translactonization cascade converting epoxide **26** to lactone **6** in 48% yield. The moderate yield of this reaction might be due to the poor solubility of **26**. Although none of the cascade intermediates could be isolated, a mechanistic rationale for this critical transformation could involve: (a) oxidation of the C-1 hydroxyl group to form ketone **27**; (b) opening of the pendant epoxide under acidic conditions to form **29**; and (c) irreversible translactonization of the C-4 hydroxyl group of **29** to produce **6**. X-ray analysis of **6** proved unambiguously that the desired E-ring of jiadifenolide has been formed (Scheme 3).^[31]

The last task toward **2** would be the installation of the C-1 methyl group and the formation of the D-ring hemiketal. To this end, enone **6** was converted to ketone **30** via hydrogenation under Pd/C conditions and subsequent silylation of the C-7 hydroxyl group (90% over 2 steps). The requirement of up to 6 bars pressure of H₂ to saturate the C-2–C-3 double bond of **6** indicated a significant steric hindrance of the A-ring. Therefore not surprisingly, direct methylation attempts to install the C-15 carbon at the C-1 center (Wittig reaction, Peterson reaction,^[34] titanium^[35] or zinc-based^[36] reagents) proved to be ineffective. Gratifyingly, a Pd(0)-catalyzed cross coupling reaction^[37] provided a solution to this challenge. Thus, chemo-selective triflation of the C-1 ketone of **30** using Comins reagent (*N*-(5-chloro-2-pyridyl)triflimide)^[38] followed by treatment with trimethylaluminum/
Pd(PPh₃)₄^[39] cleanly yielded compound **31** (57% over two steps). In turn, the C-1–C-2 double bond of **31** was selectively hydrogenated from the α -face (PtO₂, H₂, 90 bar, 24 h) to produce the desired C-1 methylated compound **32**. It should be noted that under higher pressure of H₂ (>110 bar) the hydrogenation was mildly accelerated but we observed concomitant desilylation of the C-7 triethylsilyl ether.^[40] The last functionalization at the C-10 center was inspired by Danishefsky's synthesis of jiadifenin.^[20] α -Hydroxylation with

the Davis oxaziridine^[41] produced $\langle$ -hydroxy lactone **33** (stereochemistry not assigned). Ultimately, the $\langle$ -hydroxyl group of **33** was oxidized under Jones conditions to produce, after concurrent desilylation of the C-7 silyl ether, (–)-jiadifenolide (**2**) in one-pot (33% yield over 3 steps). The isolated sample of synthetic **2** was found to be identical in all aspects with naturally occurring jiadifenolide.^[13] The absolute stereochemistry of **2** was also confirmed by X-ray analysis.^[31]

Total synthesis of (–)-jiadifenin (**3**) and (–)-ODNM (**4**)

Initial attempts to perform a C-1 radical deoxygenation of **7**^[42] en route to the synthesis of **3** were unsuccessful (Scheme 4). However, treatment of **7** with Martin sulfurane^[43] under dehydrating conditions led to diene **34** that was directly and selectively reduced under Pd/C-catalyzed hydrogenation to give compound **35** in 72% combined yield. Various reagents and methods, involving selenium-based, chromium-based, palladium-based and rhodium-based oxidants, were tested in order to oxidize the C-2 allylic center, but proved to be insufficient.^[44] Eventually, we were able to isolate small amounts of enone **36** (~10%) using $\text{Mn}_3\text{O}(\text{OAc})_9/\text{TBHP}$ ^[45] under the reported conditions (72 h, rt). Gratifyingly, this oxidation occurred much faster by raising the reaction temperature (24 h, 40 °C) increasing significantly the yield of **36** to 65%. Next in line was projected to be a chemo-selective C-1 methylation of **36** followed by α -hydroxylation at the C-10 position. However, all methylation attempts suggested that the C-10 position is more reactive, leading exclusively to monomethylated product **37**. When excess base and methyl source (such as LDA and MeI) were applied, the C-10 and C-1 dimethylated product **38** was isolated, suggesting that the significantly less hindered C-10 carbon was competing for the methylation.^[31] Based on these findings, we decided to invert the functionalization sequence. Enone **36** was initially α -hydroxylated with the Davis oxaziridine to afford the hydroxy lactone **39** (61% yield) together with dihydroxylated product **40** (19% yield). Subsequently, the C-1 methylation was performed by subjecting **39** to the LDA/MeI/HMPA conditions to produce (–)-ODNM (**4**) in 38% yield (60% brsm, based on recovered starting material). The following transformation proceeded under Jones conditions with methanolic work up leading to the isolation of jiadifenin (**3**) in 45% yield. Both synthetic **4** and **3** were found to have identical spectroscopic and analytical properties with those of the natural products.^[14,20,21]

Synthesis of designed analogues

Examination of the chemical structures of the *Illicium* natural products indicates that subtle variations at carbons C-1, C-2 and C-10 play a significant role in the neurotrophic activities of these compounds. For instance, ODNM was found to be one of the most potent neurotrophic natural products (as low as 100 nM), while the 10-*epi*-ODNM and the 1,10-*diepi*-ODNM were devoid of any activity.^[14] Synthetically, the first challenge proved to be the creation of the β -substituted C-1 methyl moiety. After several unsuccessful attempts (DBU, LDA or *t*BuOK) to invert the C-1 stereochemistry of ODNM, we were prompted to develop an alternative route that could install the C-1 methyl moiety before constructing the C-2 enone motif. To this end, the C-1 hydroxyl group of **7** was oxidized under PCC conditions (0.5 h, rt) to afford ketone **41** in 65% yield (Scheme 5). It should be noted that the Swern oxidation was ineffective while Dess-Martin-periodinane or IBX oxidations led to complete migration of the C-3–C-4 double bond to give the corresponding enone. Treatment of **41** under 2,6-bis(*tert*-butyl)-4-methylpyridine/ TiF_4 conditions selectively formed the corresponding C-1 triflate that was subsequently subjected to $\text{AlMe}_3/\text{Pd}(\text{PPh}_3)_4$ ^[39] conditions to produce diene **42**. Partial hydrogenation of **42** gave rise to compound **43** possessing the desired C-1 methyl moiety, albeit with moderate yield (23% over 3 steps). Allylic oxidation using the manganese-based conditions ($\text{Mn}_3\text{O}(\text{OAc})_9/\text{TBHP}$)^[45] was able to effectively deliver enone **45** without any C-1 epimerization (60% yield). We then

attempted a Davis-based α -hydroxylation at the C-10 center of **45**. To our surprise, we isolated (–)-ODNM (**4**) as the only product in 59% yield. The formation of **4** under these conditions can be explained by considering that the C-1 methyl group of **45** undergoes a rapid epimerization during the C-10 hydroxylation. To overcome this issue, we first reduced the C-2 carbonyl group under Luche conditions. Interestingly, this reduction was selectively accomplished from the top face of the enone motif, presumably due to the steric hindrance of the adjacent C-5 stereocenter. The resulting allylic alcohol was then converted to **46** upon treatment with NaHMDS and the Davis oxaziridine (40% combined yield). The C-10 stereochemistry could be further modified via a 2-step sequence using a Dess-Martin periodinane-based global oxidation followed by stereoselective reduction with NaBH₄ to produce **47** (40% combined yield). In a similar fashion, analogue **44** was prepared from lactone **43** using the Davis oxaziridine (57% yield). The stereochemistries of new compounds **44**, **46** and **47** have been assigned based on 2D NOESY analyses.

Evaluation of neurotrophic activity and pharmacophore mapping

Earlier studies by the Danishefsky group^[20] established that certain synthetic analogues have activities comparable to jiadifenin, further justifying the studies toward the identification of a common pharmacophoric motif. Our synthetic approach gave access to several highly active natural products and a library of designed analogues that can be used to map the unexplored neurotrophic pharmacophore. Our first task was to validate the biological profile of synthetic jiadifenolide (**2**), jiadifenin (**3**) and ODNM (**4**) with regard to NGF-mediated neurite outgrowth in PC-12 cells. This cell line undergoes neuronal differentiation into neuron-like cells with elongated neurite outgrowth in response to NGF. As such, it has been broadly applied to study NGF activity.^[20,46] The ability of synthetic natural products **2-4** to promote neurite outgrowth was measured both in the presence and absence of NGF. In the presence of NGF (50 ng/mL) a significant increase of neuronal differentiation could be observed upon 72 hours of incubation (Figure 2). Specifically, the neurite length outgrowth induced by **2**, **3** and **4** (at 0.3 μ M) was 166%, 148% and 145%, respectively (as compared to DMSO + NGF control). No outgrowth was observed in the absence of NGF, in agreement with previous findings.^[20] This supports the notion that these compounds operate by enhancing the action of NGF rather than functioning independently.^[20] Interestingly, our synthetic (–)-jiadifenin displayed similar activity with the one previously reported for racemic jiadifenin.^[20] Similar observations have been reported in the merrilactone A studies.^[18k]

We then evaluated the *in vitro* neurotrophic activity of the synthetic analogues in PC-12 cells. The results related to neurite outgrowth and the percentage of cells with neurites are summarized in Tables 1 and 2. The most active analogue was found to be enone **37** that enhanced neurite outgrowth by more than 180%. Notably, **37** contains a methyl group at C-10 and a carbonyl group at C-2 and shows superior activity in comparison to the natural products. This suggests that the hemiketal functionality of **2** and **3** might be not essential to the neurotrophic activity. The C-1 methylated analogue **38** also exhibits excellent activity, promoting neurite outgrowth by 162%. Interestingly, compounds lacking a C-10 substituent, such as **43** and **45**, have dramatically reduced neurotrophic activity. The C-1 and C-10 bis-hydroxylated analogue **40** was found to be active (138%) although less active than the bis-methylated compound **38** (162%). A comprehensive summary of these results is shown in Tables 3 and 4. The pharmacophore mapping (Table 4) suggests that all the C-10 β -substituted compounds are inactive (Table 4, row 2), while all compounds that possess a C-10 α -substituted moiety have shown moderate to excellent neurotrophic activities (Table 4, row 3 and 4). Interestingly, α -methyl substitution at C-10 increases the activity (compounds **37** and **38**) as compared to the related α -hydroxylated compounds (**39** and **40**). Moreover, C-10 non-substituted compounds were found to be all inactive (Table 1, row 1).

The pharmacophore mapping efforts thus suggests that an α -substituent at C-10 is essential to the neurotrophic activity of this family. Two pairs of compounds support this conclusion: the C-10 α -substituted compounds **4** and **46** exhibit good to excellent activities while their C-10 β -substituted diastereomers **50**^[14,15] and **47** are essentially inactive. This conclusion may also explain why many *Illicium* natural product family members possess highly similar structures with ODNM (**4**) but are devoid of neurotrophic activities. We also assume that the potent activity of jiadifenolide (**1**) and jiadifenin (**2**), might benefited from their suitable oriented C-10 hemiketalic hydroxyl group.

Conclusion

Jiadifenolide (**2**), jiadifenin (**3**) and (1*R*,10*S*)-2-oxo-3,4-dehydroxyneomajucin (**4**, ODNM), three highly neurotrophic *Illicium* natural products, have been synthesized in a divergent manner. Key to the synthesis is an enantioselective Robinson annulation reaction^[47] that produces the AB ring system **9**. Functionalization at the periphery of the B ring produces the C-ring lactone, while a one-pot oxidation and epoxide opening reaction cascade form tetracyclic motif **7**. Compound **7** represents the branching point for the synthesis of the natural product targets and designed analogues. Evaluation of the neurotrophic activities of these compounds in PC-12 cells leads to identification of simplified analogues **37** and **38** that induce more than 160% neurite outgrowth at 0.3 μ M by enhancing the activity of NGF. In addition, pharmacophore mapping studies suggest that the substituent at the C-10 center plays a critical role in the neurotrophic activity. On the other hand, the hemiketal moiety of **2** and **3** as well as the substitution at C-1 might not be important to the bioactivity. The designed strategy along with the pharmacophore mapping studies may pave the way for the rational design of potent agents against neurodegenerative diseases.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the National Institutes of Health (NIH) for financial support of this work through Grant Number CA 133002. We thank the National Science Foundation for instrumentation grants CHE9709183 and CHE0741968. We also thank Dr. Anthony Mrse (UCSD NMR Facility), Dr. Yongxuan Su (UCSD MS Facility) and Dr. Arnold L. Rheingold and Dr. Curtis E. Moore (UCSD X-Ray Facility). We appreciate the technical support from Ms. Kristine N. Wright (Dept. of Neurosciences, UCSD). We also thank W. K. Chang for synthesizing early-stage material.

References

1. For NGF discovery and characterizations, see: Cohen S, Levi-Montalcini R, Hamburger V. Proc Natl Acad Sci USA. 1954; 40:1014–1018. [PubMed: 16589582] Levi-Montalcini R, Cohen S. Proc Natl Acad Sci USA. 1956; 42:695–699. [PubMed: 16589933] McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A, Blundell TL. Nature. 1991; 354:411–414. [PubMed: 1956407]
2. For selected reviews on neurotrophins, see: Purves D. Body and Brain A Trophic Theory of Neural Connections. 1988Harvard Univ. PressCambridge, MABothwell M. Annu Rev Neurosci. 1995; 18:223–253. [PubMed: 7605062] Huang EJ, Reichardt LF. Annu Rev Neurosci. 2001; 24:677–736. [PubMed: 11520916] Chao MV. Nature Rev Neurosci. 2003; 4:299–309. [PubMed: 12671646] McAllister AK, Katz LC, Lo DC. Annu Rev Neurosci. 1999; 22:295–318. [PubMed: 10202541] Lu B, Pang PT, Woo NH. Nature Rev Neurosci. 2005; 6:603–614. [PubMed: 16062169] Chowdary PD, Che DL, Cui B. Annu Rev Phys Chem. 2012; 63:571–594. [PubMed: 22404590]
3. For selected reviews on NGF and neurodegeneration, see: Siegel GJ, Chauhan NB. Brain Res Rev. 2000; 33:199–227. [PubMed: 11011066] Holtzman DM, Mobley WC. West J Med. 1994; 161:246–254. [PubMed: 7975562] Arancio O, Chao MV. Curr Opin Neurobiol. 2010; 17:325–330. [PubMed:

- 17419049] Sofroniew MV, Howe CL, Mobley WC. *Annu Rev Neurosci.* 2001; 24:1217–1281. [PubMed: 11520933]
4. (a) Chao MV, Rajagopal R, Lee FS. *Clinical Sci.* 2006; 110:167–173. [PubMed: 16411893] (b) Lang UE, Jockers-Scherubl MC, Hellweg RJ. *Neural Transm.* 2004; 111:387–411. (c) Dwivedi Y. *Neuropshych Dis & Treatment.* 2009; 5:443–449. (d) Nagahara AH, Tuszynski MH. *Nat Rev Drug Discov.* 2011; 10:209–219. [PubMed: 21358740] (e) Pardon MC. *Vitam Horm.* 2010; 82:185–200. [PubMed: 20472139]
 5. (a) Williams BJ, Eriksdotter-Jonhagen M, Granholm AC. *Progress Neurobiol.* 2006; 80:114–128. (b) Capsoni S, Cattaneo A. *Cell Molec Neurobiol.* 2006; 26:619–633. [PubMed: 16944323] (c) Capsoni S, Giannotta S, Cattaneo A. *Proc Natl Acad Sci USA.* 2002; 99:12432–12437. [PubMed: 12205295] (d) Citron M. *Nature Rev Neurosci.* 2004; 5:677–685. [PubMed: 15322526]
 6. (a) Skaper SD. *CNS & Neurological Disorders – Drug Targets.* 2008; 7:46–62. [PubMed: 18289031] (b) Martinez, A. *Emerging drugs and targets for Alzheimer's disease.* Vol. 1, 2. RSC Publishing; Cambridge, UK: 2010. (c) Skaper SD, Walsh FS. *Mol Cell Neurosci.* 1998; 12:179–193. [PubMed: 9828084] (d) Hefti F. *Annu Rev Pharmacol Toxicol.* 1997; 37:239–267. [PubMed: 9131253] (e) Longo FM, Yang T, Xie YM, Massa SM. *Curr Alzheimer Res.* 2006; 3:5–10. [PubMed: 16472196] (f) Rishton GM. *Recent Pat CNS Drug Discov.* 2008; 3:200–208. [PubMed: 18991809] (g) Citron M. *Nature Rev Drug Discov.* 2010; 9:387–398. [PubMed: 20431570] (h) Williams P, Sorribas A, Howes MJ. *Nat Prod Rep.* 2011; 28:48–77. [PubMed: 21072430]
 7. For selected examples, see: Corey EJ, Reichard GA. *J Am Chem Soc.* 1992; 114:10677–10678. Nagamitsu T, Sunazuka T, Tanaka H, Omura S, Sprengeler PA, III Smith AB. *J Am Chem Soc.* 1996; 118:3584–3590. Waters SP, Tian Y, Li YM, Danishefsky SJ. *J Am Chem Soc.* 2005; 127:13514–13515. [PubMed: 16190712] Wilson RM, Danishefsky SJ. *Acc Chem Res.* 2006; 39:539–549. [PubMed: 16906750] Cook SP, Polara A, Danishefsky SJ. *J Am Chem Soc.* 2006; 128:16440–16441. [PubMed: 17177359] Beshore DC, Smith AB III. *J Am Chem Soc.* 2007; 129:4148–4149. [PubMed: 17367142] Min SJ, Danishefsky SJ. *Angew Chem Int Ed.* 2007; 46:2199–2202. Rawat M, Gama CI, Matson JB, Hsieh-Wilson L. *J Am Chem Soc.* 2008; 130:2959–2961. [PubMed: 18275195] Bisai A, West SP, Sarpong R. *J Am Chem Soc.* 2008; 130:7222–7223. [PubMed: 18479095] Jessen HJ, Barbaras D, Hamburger M, Gademann K. *Org Lett.* 2009; 11:3446–3449. [PubMed: 19586047] Chen APJ, Mueller CC, Cooper HM, Williams CM. *Org Lett.* 2009; 11:3758–3761. [PubMed: 19624119] Wang Z, Min SJ, Danishefsky SJ. *J Am Chem Soc.* 2009; 131:10848–10849. [PubMed: 19722666] Schmidt F, Champy P, Seon-Meniel B, Franck X, Raisman-Vozari R, Figadere B. *PLOS One.* 2009; 4:e6215. [PubMed: 19593444] Jang SW, Liu X, Chan CB, France SA, Sayeed I, Tang WX, Lin X, Xiao G, Andero R, Chang Q, Ressler KJ, Ye KQ. *PLOS One.* 2010; 5:e11528. [PubMed: 20644624] Yuan C, Chang CT, Axelrod A, Siegel D. *J Am Chem Soc.* 2010; 132:5924–5925. [PubMed: 20387896] Fischer DF, Sarpong R. *J Am Chem Soc.* 2010; 132:5926–5927. [PubMed: 20387895] Nishimura T, Unni AK, Yokoshima S, Fukuyama T. *J Am Chem Soc.* 2011; 133:418–419. [PubMed: 21155564] Jana CK, Hoecker J, Woods TM, Jessen HJ, Neuburger M, Gademann K. *Angew Chem Int Ed.* 2011; 50:8407–8411. Scott LE, Telpoukhovskaia M, Rodriguez-Rodriguez C, Merkel M, Bowen ML, Page BDG, Green DE, Storr T, Thomas F, Allen DD, Lockman PR, Patrick BO, Adam MJ, Orvig C. *Chem Sci.* 2011; 2:642–648. Tun MKM, Wüstmann DJ, Herzon SB. *Chem Sci.* 2011; 2:2251–2253. Cheng X, Harzendorf N, Khaing Z, Kang D, Camelio AM, Shaw T, Schmidt CE, Siegel D. *Org Biomol Chem.* 2012; 10:383–393. [PubMed: 22083452] Elamparuthi E, Fellay C, Neuburger M, Gademann K. *Angew Chem Int Ed.* 2012; 51:4071–4073.
 8. (a) Iriti M, Vitalini S, Fico G, Faoro F. *Molecules.* 2010; 15:3517–3555. [PubMed: 20657497] (b) Corson TW, Crews CM. *Cell.* 2007; 130:769–774. [PubMed: 17803898] (c) Joyner PM, Cichewicz RH. *Nat Prod Rep.* 2011; 28:26–47. [PubMed: 20927454] (d) Longo FM, Xie Y, Massa SM. *Curr Med Chem – Central Nervous System Agents.* 2005; 5:29–41. (e) O'Neill MJ, Messenger MJ, Lakics V, Murray TK, Karran EH, Szekeres PG, Nisenbaum ES, Merchant KM. *Int Rev Neurobiol.* 2007; 77:179–217. [PubMed: 17178475] (f) Price RD, Milne SA, Sharkey J, Matsuoka N. *Pharmacol Ther.* 2007; 115:292–306. [PubMed: 17599430]
 9. For a recent monograph on this topic see: *Natural Products for Neurodegenerative Diseases.* Wong YH, Kong H, Wong JTY, Kong H. *Neurosignals.* Karger, AGBasel2005
 10. Kannappan R, Gupta SC, Kim JH, Reuter S, Aggarwal BB. *Mol Neurobiol.* 2011; 44:142–159. [PubMed: 21360003]

11. For review of natural products from *Illicium* species, see: Fukuyama Y, Huang JM. Studies in Natural Products Chemistry. 32Atta-ur-Rahman. ElsevierAmsterdam2005; :395–429.
12. (a) Yang CS, Kouno I, Kawano N, Sato S. Tetrahedron Lett. 1988; 29:1165–1168.(b) Kouno I, Baba N, Hashimoto M, Kawano N, Takahashi M, Kaneto H, Yang CS, Sato S. Chem Pharm Bull. 1989; 37:2448–2451.
13. Kubo M, Okada C, Huang JM, Harada K, Hioki H, Fukuyama Y. Org Lett. 2009; 11:5190–5193. [PubMed: 19873982]
14. Yokoyama R, Huang JM, Yang CS, Fukuyama Y. J Nat Prod. 2002; 65:527–531. [PubMed: 11975494]
15. Kouno I, Baba N, Hashimoto M, Kawano N, Takahashi M, Kaneto H, Yang CS. Chem Pharm Bull. 1990; 38:422–425.
16. For a review of total syntheses of natural products from *Illicium* species, see: Urabe D, Inoue M. Tetrahedron. 2009; 65:6271–6289.
17. (a) Niwa H, Nishiwaki M, Tsukada I, Ishigaki T, Ito S, Wakamatsu K, Mori T, Ikagawa M, Yamada K. J Am Chem Soc. 1990; 112:9001–9003.(b) Ogura A, Yamada K, Yokoshima S, Fukuyama T. Org Lett. 2012; 14:1632–1635. [PubMed: 22369157]
18. (a) Birman VB, Danishefsky SJ. J Am Chem Soc. 2002; 124:2080–2081. [PubMed: 11878938] (b) Inoue M, Sato T, Hiramama M. J Am Chem Soc. 2003; 125:10772–10773. [PubMed: 12952441] (c) Harada K, Kato H, Fukuyama Y. Tetrahedron Lett. 2005; 46:7407–7410.(d) Iriondo-Alberdi J, Perea-Buceta JE, Greaney MF. Org Lett. 2005; 7:3969–3971. [PubMed: 16119944] (e) Mehta G, Singh SR. Tetrahedron Lett. 2005; 46:2079–2082.(f) Meng ZY, Danishefsky SJ. Angew Chem Int Ed. 2005; 44:1511–1513.(g) Inoue M, Sato T, Hiramama M. Angew Chem Int Ed. 2006; 45:4843–4848.(h) Mehta G, Singh SR. Angew Chem Int Ed. 2006; 45:953–955.(i) Harada K, Ito H, Hioki H, Fukuyama Y. Tetrahedron Lett. 2007; 48:6105–6108.(j) He W, Huang J, Sun XF, Frontier AJ. J Am Chem Soc. 2007; 129:498–499. [PubMed: 17227006] (k) Inoue M, Lee N, Kasuya S, Sato T, Hiramama M, Moriyama M, Fukuyama Y. J Org Chem. 2007; 72:3065–3075. [PubMed: 17355151] (l) He W, Huang J, Sun XF, Frontier AJ. J Am Chem Soc. 2008; 130:300–308. [PubMed: 18067294] (m) Shi L, Meyer K, Greaney MF. Angew Chem Int Ed. 2010; 49:9250–9253.(n) Chen JW, Gao P, Yu FM, Yang Y, Zhu SZ, Zhai HB. Angew Chem Int Ed. 2012; 51:5897–5899.(o) Nazef N, Davies RDM, Greaney MF. Org Lett. 2012; 14:3720–3723.
19. (a) Harada K, Imai A, Uto K, Carter RG, Kubo M, Hioki H, Fukuyama Y. Org Lett. 2011; 13:988–991. [PubMed: 21265560] (b) Mehta G, Shinder HM, Kumaran RS. Tetrahedron Lett. 2012; 53:4320–4323.
20. (a) Cho YS, Carcache DA, Tian Y, Li YM, Danishefsky SJ. J Am Chem Soc. 2004; 126:14358–14359. [PubMed: 15521747] (b) Carcache DA, Cho YS, Hua Z, Tian Y, Li YM, Danishefsky SJ. J Am Chem Soc. 2006; 128:1016–1022. [PubMed: 16417394]
21. Yang Y, Fu X, Chen J, Zhai H. Angew Chem Int Ed. 2012; 51:9825–9828.
22. (a) Xu J, Trzoss L, Chang WK, Theodorakis EA. Angew Chem Int Ed. 2011; 50:3672–3676.(b) Trzoss L, Xu J, Lacoske MH, Mobley WC, Theodorakis EA. Org Lett. 2011; 13:4554–4557. [PubMed: 21812392]
23. (a) Ruprah PK, Cros JP, Pease JE, Whittingham WG, Williams MJ. Eur J Org Chem. 2002:3145–3152.(b) Lacoste E, Vaique E, Berlande M, Pianet I, Vincent JM, Landais Y. Eur J Org Chem. 2007:167–177.(c) Zhang XM, Wang M, Tu YQ, Fan CA, Jiang YJ, Zhang SY, Zhang FM. Synlett. 2008:2831–2835.
24. (a) Hardinger SA, Wijaya N. Tetrahedron Lett. 1993; 34:3821–3824.(b) Ghosh S, Rivas F, Fischer D, González MA, Theodorakis EA. Org Lett. 2004; 6:941–944. [PubMed: 15012070]
25. (a) Finkbeiner HL, Stiles M. J Am Chem Soc. 1963; 85:616–622.(b) Micheli RA, Hajos ZG, Cohen N, Parrish DR, Portland LA, Sciamanna W, Scott MA, Wehrli PA. J Org Chem. 1975; 40:675–681. [PubMed: 1133631] (c) Frie JL, Jeffrey CS, Sorensen E. J Org Lett. 2009; 11:5394–5397.
26. (a) Meerwein H, Hinz G, Hofmann P, Kroning E, Pfeil E. J Prakt Chem. 1937; 147:257–285.(b) Meerwein H, Bettenberg E, Gold H, Pfeil E, Willfang G. J Prakt Chem. 1939; 154:83–156.(c) Raber DJ, Gariano P Jr, Brod AO, Gariano A, Guida WC, Guida AR, Herbst MD. J Org Chem. 1979; 44:1149–1154.

27. (a) Stork G, Sofia MJ. *J Am Chem Soc.* 1986; 108:6826–6828. (b) Radunz HE, Schneider G. *Angew Chem.* 1985; 97:129–131. (c) Kende AS, Chen J. *J Am Chem Soc.* 1985; 107:7184–7186. (d) Jiang X, Covey DF. *J Org Chem.* 2002; 67:4893–4900. [PubMed: 12098302]
28. Lee HM, Nieto-Oberhuber C, Shair MD. *J Am Chem Soc.* 2008; 130:16864–16866. [PubMed: 19053422]
29. (a) McMurry JE, Scott WJ. *Tetrahedron Lett.* 1983; 24:979–982. (b) Scott WJ, McMurry JE. *Acc Chem Res.* 1988; 21:47–54.
30. Cowell A, Stille JK. *J Am Chem Soc.* 1980; 102:4193–4198. Cacchi S, Morera E, Ortari G. *Tetrahedron Lett.* 1985; 26:1109–1112. For another interesting methoxycarbonylation method, see: Drent E, Arnoldy P, Budzelaar PHM. *J Organomet Chem.* 1993; 455:247–253. Magro AAN, Robb LM, Pogorzelec PJ, Slawin AMZ, Eastham GR, Cole-Hamilton DJ. *Chem Sci.* 2010; 1:723–730.
31. CCDC 807620 (**22**), CCDC 888971 (**23**), CCDC 888972 (**26**), CCDC 807621 (**6**) and CCDC 807950 (**2**), CCDC831791 (**37**) and CCDC831792 (**38**) contain the supplementary crystallographic data for corresponding compounds. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/products/csd/request/.
32. (a) Wallis JM, Kochi JK. *J Org Chem.* 1988; 53:1679–1686. (b) Feigelson GB, Egbertson M, Danishefsky SJ, Schulte G. *J Org Chem.* 1988; 53:3390–3391. (c) Pegg NA, Paquette LA. *J Org Chem.* 1991; 56:2461–2468. (d) Yaji K, Shindo M. *Tetrahedron.* 2010; 66:9808–9813.
33. (a) David F. *J Org Chem.* 1981; 46:3512–3519. (b) Künzer H, Thiel M. *Tetrahedron Lett.* 1995; 36:1237–1238. (c) Hoveyda AH, Evans DA, Fu GC. 1993; 93:1307–1370.
34. Peterson DJ. *J Org Chem.* 1968; 33:780–784.
35. (a) Tebbe FN, Parshall GW, Reddy GS. *J Am Chem Soc.* 1978; 100:3611–3613. (b) Petasis NA, Bzowej EI. *J Am Chem Soc.* 1990; 112:6392–6394.
36. (a) Nysted, LN. US Patent 3865848. 1975. (b) Lombardo L. *Tetrahedron Lett.* 1982; 23:4293–4296.
37. For review of palladium-catalyzed cross-coupling reactions in total synthesis, see: Nicolaou KC, Bulger PG, Sarlah D. *Angew Chem Int Ed.* 2005; 44:4442–4489.
38. (a) Comins DL, Dehghani A. *Tetrahedron Lett.* 1992; 33:6299–6302. (b) Comins DL, Dehghani A, Foti CJ, Joseph SP. *Org Synth.* 1997; 74:77. 1998, Coll 9, 165.
39. (a) Hirota K, Isobe Y, Maki Y. *J Chem Soc Perkin Trans.* 1989; 1:2513–2514. (b) Saulnier MG, Kadow JF, Tun MM, Langley DR, Vyas DM. *J Am Chem Soc.* 1989; 111:8320–8321. (c) Winkler JD, Doherty EM. *J Am Chem Soc.* 1999; 121:7425–7426.
40. Rotulo-Sims D, Prunet J. *Org Lett.* 2002; 4:4701–4704. [PubMed: 12489965]
41. (a) Davis FA, Chattopadhyay S, Towson JC, Lal S, Reddy T. *J Org Chem.* 1988; 53:2087–2089. (b) Vishwakarma LC, Stringer OD, Davis FA. *Org Synth Coll.* 1993; 8:546. (c) Davis FA, Chen BC. *Chem Rev.* 1992; 92:919–934.
42. Barton DHR, McCombie SW. *J Chem Soc Perkin Trans 1.* 1975; 16:1574–1585.
43. (a) Martin JC, Arhart RJ. *J Am Chem Soc.* 1971; 93:4327–4329. (b) Arhart RJ, Martin JC. *J Am Chem Soc.* 1972; 94:5003–5010. (c) Martin JC, Franz JA, Arhart RJ. *J Am Chem Soc.* 1974; 96:4604–4611.
44. For examples of metal-based allylic oxidation, see: **Bi-based:** Salvador JAR, Silvestre SM. *Tetrahedron Lett.* 2005; 46:2581–2584. **Cr-based:** Dauben WG, Lorber ME, Fullerton DS. *J Org Chem.* 1969; 34:3587–3592. Pearson AJ, Chen YS, Hsu SY, Ray T. *Tetrahedron Lett.* 1984; 25:1235–1238. Foustieris MA, Koutsourea AI, Nikolaropoulos SS, Riahi A, Muzart J. *J Mol Catal A: Chem.* 2006; 250:70–74. Muzart J. *Chem Rev.* 1992; 92:113–140. **Co-based:** Salvador JAR, Clark JH. *Chem Commun.* 2001; 6:33–34. Jurado-Gonzalez M, Sullivan AC, Wilson JRH. *Tetrahedron Lett.* 2003; 44:4283–4286. **Cu-based:** Salvador JAR, Sáe Melo ML, Campos Neves AS. *Tetrahedron Lett.* 1997; 38:119–122. Arsenou ES, Koutsourea AI, Foustieris MA, Nikolaropoulos SS. *Steroids.* 2003; 68:407–414. [PubMed: 12798491] **Fe-based:** Barton DRH, Le Gloahec VN. *Tetrahedron.* 1998; 54:15457–15468. **iodonium-based:** Zhao Y, Yeung YY. *Org Lett.* 2010; 12:2128–2131. [PubMed: 20387842] **Pd-based:** McMurry JE, Kotovský P. *Tetrahedron Lett.* 1984; 25:4187–4190. Yu JQ, Corey EJ. *J Am Chem Soc.* 2003; 125:3232–3233. [PubMed: 12630876] Yu JQ, Wu HC, Corey EJ. *Org Lett.* 2005; 7:1415–1417. [PubMed:

15787520] Chen MS, White MC. *J Am Chem Soc.* 2004; 126:1346–1347. [PubMed: 14759185] Chen MS, Prabakaran N, Labenz NA, White MC. *J Am Chem Soc.* 2005; 127:6970–6971. [PubMed: 15884938] Fraunhoffer KJ, Prabakaran N, Sirois LE, White MC. *J Am Chem Soc.* 2006; 128:9032–9033. [PubMed: 16834366] Delcamp JH, White MC. *J Am Chem Soc.* 2006; 128:15076–15077. [PubMed: 17117844] Covell DJ, White MC. *Angew Chem Int Ed.* 2008; 47:6448–6451. Stang EM, White MC. *Nature Chem.* 2009; 1:547–551. [PubMed: 21378935] **Rh-based:** Catino AJ, Forslund RE, Doyle MP. *J Am Chem Soc.* 2004; 126:13622–13623. [PubMed: 15493912] Catino AJ, Nichols JM, Choi H, Gottipamula S, Doyle MP. *Org Lett.* 2005; 7:5167–5170. [PubMed: 16268529] Choi H, Doyle MP. *Org Lett.* 2007; 9:5349–5352. [PubMed: 18027961] McLaughlin EC, Doyle MP. *J Org Chem.* 2008; 73:4317–4319. [PubMed: 18447390] McLaughlin EC, Choi H, Wang K, Chiou G, Doyle MP. *J Org Chem.* 2009; 74:730–738. [PubMed: 19072696] **Selenium based:** Warpehoski MA, Chabaud B, Sharpless KB. *J Org Chem.* 1982; 47:2897–2900. Xu J, Caro-Diaz EJE, Trzoss L, Theodorakis EA. *J Am Chem Soc.* 2012; 134:5072–5075. [PubMed: 22390338] Xu J, Caro-Diaz EJE, Lacoske MH, Hung CI, Jomora C, Theodorakis EA. *Chem Sci.* 2012; 3:3378–3386. [PubMed: 23227303] **Sodium chlorite:** Silvestre SM, Salvador JAR. *Tetrahedron.* 2007; 63:2439–2445.

45. Shing TKM, Yeung YY, Su PL. *Org Lett.* 2006; 8:3149–3151. [PubMed: 16805574]
46. Greene LA, Tischler AS. *Proc Natl Acad Sci USA.* 1976; 73:2424–2428. [PubMed: 1065897]
47. For selected natural product syntheses from the Theodorakis group using asymmetric Robinson annulations see: Ling TT, Xiang AX, Theodorakis EA. *Angew Chem Int Ed.* 1999; 38:3089–3091. Ling TT, Poupon E, Rueden EJ, Kim SH, Theodorakis EA. *J Am Chem Soc.* 2002; 124:12261–12267. [PubMed: 12371868] Ling T, Poupon E, Rueden EJ, Theodorakis EA. *Org Lett.* 2002; 4:819–822. [PubMed: 11869136] Brady TP, Kim SH, Wen K, Theodorakis EA. *Angew Chem Int Ed.* 2004; 43:739–742. Brady TP, Kim SH, Wen K, Kim C, Theodorakis EA. *Chem – Eur J.* 2005; 11:7175–7190. [PubMed: 16163770] Ling T, Xu J, Smith R, Ali A, Cantrell CL, Theodorakis EA. *Tetrahedron.* 2011; 67:3023–3029. [PubMed: 21643472] Nguyen TX, Dakanali M, Trzoss L, Theodorakis EA. *Org Lett.* 2011; 13:3308–3311. [PubMed: 21615125] . For a recent update of Robinson annulation, see: Peng F, Dai MJ, Angeles AR, Danishefsky SJ. *Chem Sci.* 2012; 3:3076–3080. [PubMed: 23139855]

Figure 1.
Structures of selected neurotrophic majucin-subtype *Illicium* sesquiterpenes and their common scaffold.

Figure 2.

Neurite outgrowth studies with selected synthetic compounds in PC-12 cells. All compounds were dissolved in 1% DMSO (v/v) and tested at a concentration of 0.3 μ M in presence of 50 ng/mL of NGF, 1% DMSO (v/v) in presence of 50 ng/mL of NGF as the control.

Scheme 1. Unified retrosynthetic strategy for jiadifenolide, jiadifenin and ODNM

Scheme 2.

Scalable synthesis of tetracyclic scaffold **7**. Reagents and conditions: (a) *N,O*-bis(trimethylsilyl)acetamide (1.0 equiv), allyl acetate (1.0 equiv), Pd(allyl)Cl₂ (0.01 equiv), DPPE (0.05 equiv), NaOAc (0.03 equiv), 70 °C, 40 h; (b) methyl vinyl ketone (2.0 equiv), H₂O/AcOH, 100 °C, 4 h, 63% from **10**; (c) D-prolinamide (0.3 equiv), PPTS (0.3 equiv), MeCN, 40 °C, 14 d, 74% (>90% *ee*); (d) NaBH₄ (0.25 equiv), EtOH, 0 °C, 1 h; (e) TBSCl (2.0 equiv), NH₄NO₃ (3.0 equiv), DMF, rt, 12 h, 92% from **9**; (f) Stiles' reagent (methyl methoxymagnesium carbonate, 4.0 equiv), DMF, 130 °C, 3 h, then Et₃O⁺BF₄⁻ (1.0 equiv), *i*Pr₂NEt (1.5 equiv), CH₂Cl₂, 0 °C, 5 min; (g) TMSOTf (1.3 equiv), 2,6-lutidine (2.0 equiv), CH₂Cl₂, 0 °C to rt, 1 h; (h) TBAF (1.0 equiv), MeI (10 equiv), THF, -78 °C to rt, 3 h, 43% from **12**; (i) LiAlH₄ (7.5 equiv), THF, 0 °C to rt, 1 h; (j) TBSCl (1.1 equiv), imidazole (2.0 equiv), CH₂Cl₂, 0 °C, 30 min; (k) IBX (3.0 equiv), DMSO, 80 °C, 1 h, 85% from **15**; (l) KHMDS (5.0 equiv), PhNTf₂ (3.0 equiv), THF, -78 °C, 1 h, 95%; (m) NH₂NH₂ (3.0 equiv), Et₃N (4.0 equiv), EtOH, 50 °C, 5 h, then I₂ (10 equiv), DBU (6.0 equiv), Et₂O, 0 °C, 80%; (n) CO (1 atm), Pd(PPh₃)₄ (0.01 equiv), MeOH/DMF (1:3), Et₃N (3.0 equiv), 50 °C, 2 h, from **17**: 60% (**19**) and 22% (**8**); from **18**: 61% (**19**) and 23% (**8**); (o) TFA (3.0 equiv), CH₂Cl₂, rt, 5 h, 85%; (p) H₂O₂ (10 equiv), 3M NaOH, THF, 0 °C to rt, 5 h, 99%; (q) OsO₄ (0.01 equiv), NaIO₄ (4.0 equiv), 2,6-lutidine (2.0 equiv), 1,4-dioxane/H₂O (3:1), rt, 12 h; (r) Jones reagent (6.0 equiv), acetone, 0 °C, 30 min, 70% of **22** and 20% of **23**; (s) TBAF (2.0 equiv), THF, rt, 30 min, 95%. The TBS group of **22** and some hydrogen atoms in the X-ray structure were omitted for clarity.

Scheme 3.

Total synthesis of (-)-jiadifenolide (**2**) from core intermediate **7**. Reagents and conditions:

(a) Reagents and conditions: (a) OsO₄ (1.0 equiv), THF/pyridine (2:1), rt, 30 min, 90%; (b) Na₂S₂O₃ (10 equiv), MeOH/H₂O (3:1), 60 °C, 1 h, 87%; (c) *m*CPBA (4.0 equiv), THF, 50 °C, 3 h; (d) Dess–Martin periodinane (2.0 equiv), acetone, rt, 2 h, 38% from **7**; (e) H₂ (6 atm), 10% Pd/C (0.05 equiv), MeOH, rt, 24 h; (f) TESOTf (2.0 equiv), 2,6-lutidine (4.0 equiv), THF, 0 °C to rt, 30 min, 90% for 2 steps; (g) KHMDS (1.5 equiv), Comins reagent (*N*-(5-chloro-2-pyridyl)triflimide, 1.1 equiv), THF, -78 °C to rt, 1.5 h; (h) AlMe₃ (20 equiv), Pd(PPh₃)₄ (0.5 equiv), THF, rt, 2 h, 57% from **30**; (i) H₂ (90 atm), PtO₂ (0.2 equiv), MeOH, rt, 24 h; (j) NaHMDS (4.0 equiv), (±)-*trans*-2-(phenylsulfonyl)-3-phenyloxaziridine (5.0 equiv), THF, -78 °C to rt, 1.5 h; (k) Jones reagent (5.0 equiv), acetone, 0 °C, 15 min, 33% for 3 steps. Some hydrogen atoms were omitted for X-ray structure clarity.

Scheme 4.

Total synthesis of (-)-jiadifenin (3) and (-)-ODNM (4) from core intermediate 7. Reagents and conditions: (a) Martin sulfurane (6.0 equiv), THF, rt, 2 h; (b) H₂ (1.1 atm), 10% Pd/C (0.3 equiv), MeOH, 30 min, 72% from 8; (c) *t*-BuOOH (10 equiv), Mn₃O(OAc)₉ (0.2 equiv), EtOAc, 3 Å MS, 40 °C, 16 h, 65%; (d) LDA (5.0 equiv), MeI (3.0 equiv), THF, -78 °C to -10 °C, 1.5 h, 50% of 39 and 25% of 40; (e) NaHMDS (3.0 equiv), (±)-*trans*-2-(phenylsulfonyl)-3-phenyloxaziridine (1.0 equiv), THF, -78 °C, 30 min, 61% of 41 and 19% of 42; (f) LDA (5.0 equiv), MeI (1.2 equiv), HMPA (1.2 equiv), THF, -78 °C to -10 °C, 5 h, 38% (60% brsm); (g) Jones reagent (15 equiv), acetone, rt, 20 min, then MeOH, 15 min, 45%. Some hydrogen atoms were omitted for X-ray structure clarity.

Scheme 5.

Synthesis of designed analogues from core intermediate **7**. Reagents and conditions: (a) pyridinium chlorochromate (2.0 equiv), Celite[®], CH₂Cl₂, rt, 30 min, 65%; (b) Tf₂O (2.0 equiv), 2,6-di-*tert*-butyl-4-methylpyridine (3.0 equiv), THF, 0 °C to rt, 12 h; (c) AlMe₃ (10 equiv), Pd(PPh₃)₄ (0.3 equiv), THF, rt, 1 h; (d) H₂ (3 atm), Pd/C (10% w/w), MeOH, 3 h, 23% from **43**; (e) NaHMDS (2.5 equiv), (±)-*trans*-2-(phenylsulfonyl)-3-phenyloxaziridine (1.1 equiv), THF, -78 °C, 30 min, 57%; (f) *t*-BuOOH (10 equiv), Mn₃O(OAc)₉ (0.2 equiv), EtOAc, 3 Å MS, 40 °C, 16 h, 60%; (g) NaHMDS (3.0 equiv), (±)-*trans*-2-(phenylsulfonyl)-3-phenyloxaziridine (1.0 equiv), THF, -78 °C, 30 min, 59%; (h) NaBH₄ (3.0 equiv), CeCl₃·7H₂O (3.0 equiv), THF/MeOH (3:1), -78 °C to -50 °C, 30 min; (i) NaHMDS (2.5 equiv), (±)-*trans*-2-(phenylsulfonyl)-3-phenyloxaziridine (1.1 equiv), THF, -78 °C, 10 min, 40% for 2 steps; (j) Dess–Martin periodinane (2.0 equiv), THF, rt, 2 h; (k) NaBH₄ (3.0 equiv), MeOH, -20 °C, 1 h, 40% for 2 steps.

Table 1

Length of neurite outgrowth. All compounds were dissolved in 1% DMSO (v/v) and tested at concentration of 0.3 μ M in presence of 50 ng/mL of NGF. C*= control: 50 ng/mL of NGF and 1% DMSO (v/v).

Table 2

Percentage of cells with neurites. All compounds were dissolved in 1% DMSO (v/v) and tested at concentration of 0.3 μ M in presence of 50 ng/mL of NGF. C*= control: 50 ng/mL of NGF and 1% DMSO (v/v).

Table 3

Neurite outgrowth studies of *illicium* natural products and analogues. All compounds were dissolved in 1% DMSO (v/v) and tested at concentration of 0.3 μ M in presence of 50 ng/mL of NGF, 1% DMSO (v/v) in presence of 50 ng/mL of NGF as the control;

2 , 166%	3 , 148%	4 , 145%	6 , 109%	7 , 104%	8a , ^b 103%

23 , 104%	26 , 106%	37 , 183%	38 , 162%	39 , 121% ²⁰	40 , 138%

43 , 94%	44 , 110%	45 , 96%	45a , 104%	46 , 147%	47 , 103%

^b prepared from **8** upon treatment with TBAF in THF at rt for 1 h.

Table 4

Pharmacophore mapping. Due to the highly substrate-controlled diastereoselectivity profile, some compounds are only available with certain stereochemistry on C-10 and C-1 positions; “inactive” indicates less than 110% of neurite outgrowth as compared to control; “active” indicates equal or greater than 110% of neurite outgrowth as compared to control.

	45a , inactive	47 , inactive	46 , active	-
	7 , inactive	-	-	-
	45 , inactive	-	44 , active	-
	-	-	40 , active	-
	48 , inactive ²⁰	50 , inactive ¹⁴	4 , active	38 , active
	-	49 , inactive ¹⁴	-	-
	36 , inactive ²⁰	-	39 , active	37 , active

Chemistry. Author manuscript; available in PMC 2014 May 10.